Companies: 10,795·Total market cap: $144.5T
Privia Health Group, Inc.

Privia Health Group, Inc.

PRVANASDAQHealthcare● Active
$21.41
$-0.22(-1.02%)
Market Cap$2.7B
P/E Ratio
52W High$26.51
52W Low$18.77

Privia Health Group, Inc. (PRVA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

prva · stock forecast · 22 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 22 Wall Street analysts in the past 3 months

SellBuy

Buy

22 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
20
Hold
2
Sell
0
Strong Sell
0
Total: 22 · Buy rate: 90.9%

12-Month Price Target

High

$36.00

Consensus

$30.00

+40.1% upside

Low

$24.00

Median: $31 · Last Close: $21.41

The Privia Health Group, Inc. (PRVA) analyst consensus is Buy, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month PRVA price target is $30.00, representing +40.1% upside from the current price of $21.41.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $30 (40.1%)

Consensus Target

$30.00

40.1% upside

High Target

$36

68.1%

Low Target

$24

12.1%

Current Price

$21.41

as of today

Based on analyst price targets, the PRVA stock price prediction for the next 12 months ranges from $24 to $36. The consensus PRVA price forecast of $30.00 implies 40.1% upside from the current price of $21.41.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$20.772.99%

1-day model range: $20.7–$20.84. Peak: $20.84 (-2.99%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$16-23.6%
2028$14-34.4%
2029$13-40.0%
2030$12-43.0%
2031-44.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%0%79%
3Buy
0Neutral
11Sell
RSI (14)24.8Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · PRVA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$21.17BUY
MA 10$21.42SELL
MA 20$22.22SELL
MA 50$22.76SELL
MA 100$22.64SELL
MA 200$23.25SELL
Current $PRVA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$21.38BUY
EMA 10$21.59SELL
EMA 20$22.07SELL
EMA 50$22.56SELL
EMA 100$22.75SELL
EMA 200$22.80SELL
Current $PRVA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Barclays2026-05-26
Maintains
Equal WeightEqual Weight
Canaccord Genuity2026-05-08
Maintains
BuyBuy
Evercore ISI Group2026-04-08
Maintains
OutperformOutperform
Barclays2026-03-25
Maintains
Equal WeightEqual Weight
Citigroup2026-03-03
Maintains
BuyBuy
Truist Securities2026-03-02
Maintains
BuyBuy
Canaccord Genuity2026-02-27
Maintains
BuyBuy
Stephens & Co.2025-12-04
Maintains
OverweightOverweight
JP Morgan2025-11-13
Maintains
OverweightOverweight
Canaccord Genuity2025-11-12
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Privia Health Group, Inc. (PRVA) stock. Of the recent 75 rating actions, 1 were upgrades and 1 were downgrades. 22 analysts currently cover PRVA.

Analyst Recommendation Trends

Buy ratings514
Hold ratings11
Sell ratings00

PRVA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$2.4B

↓ 17.9% YoY

Revenue Next Year

$2.7B

↑ 10.0% YoY

EPS This Year

$0.25

EPS Next Year

$0.41

↑ 61.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PRVA EPS of $0.25 for the current fiscal year, based on estimates from 10 analysts. The PRVA revenue forecast is $2.4B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PRVA stock forecast is supported by two independent data sources: analyst consensus ratings from 22 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PRVA price target is $30.00 (+40.1% upside), with an analyst consensus of Buy.

The PRVA short-term stock prediction for tomorrow is $20.77 (-2.99%). The PRVA stock price prediction for 2027 estimates an average of $16. The PRVA stock prediction for 2030 projects a range of $12–$13.

Privia Health Group, Inc. trades on NASDAQ under the ticker PRVA. The PRVA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 91% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PRVA forecast · 8 questions

According to 22 Wall Street analysts, the average 12-month PRVA price target is $30.00, with a high forecast of $36.00 and a low of $24.00. The median price target is shown in the chart above when available. This implies +40.1% potential upside from the current price of $21.41.

PRVA price targetWhat is PRVA price targetPRVA analyst price targetPRVA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.